Advisories For Registrants
June 17th, 2024
Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
June 10th, 2024
Important Safety and Efficacy Information on ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) – Market Withdrawal and Continued Restricted Access
June 6th, 2024
Importation of USA-authorized Carbamazepine Extended-Release Tablets, USP 200 mg and 400 mg due to the current shortage of Canadian-authorized carbamazepine
Advisories For The Public
August 5th, 2024
Expanded recall: ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and 0.05% mild lotion recalled due to an impurity that may pose health risks
August 5th, 2024
JAMP Digoxin 0.0625 mg and 0.125 mg tablets recalled due to possible incorrect dose, which may pose health risks
July 29th, 2024
Various multivitamins and supplements distributed across Canada are being recalled because they may contain metal fibres
July 26th, 2024
Incorrect dosing information on the “SAVE ME” instructional card in the Naloxone Take Home Kit by Canadian Hospital Specialties Ltd
June 17th, 2024
Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
June 10th, 2024
Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone tablets recalled due to data integrity concerns
The Newfoundland & Labrador Pharmacy Board (NLPB) is excited to embark on the next three years (2020-2022) with the Board approved goals and objectives outlined in this document.
In early 2019, a strategic planning and development session with Board members and NLPB staff took place to discuss challenges and opportunities for NLPB—the pharmacy regulator in Newfoundland & Labrador.
It was determined that these goals support NLPB’s vision of advancing pharmacy care for a safe and healthy community, and successfully reflect the organizations core values of accountability, collaboration, integrity, respect and transparency.
The goals encourage a positive patient experience with a focus on:
- strengthening the professional identity of pharmacy professionals to foster greater pride in providing high quality care for each and every patient
- reviewing and streamlining governing documents for simplicity and ease of use for registrants
- enhancing the quality assurance program to ensure the mandate of public protection is achieved through prompting registrant competency, high standards of practice, and to align with national quality improvement initiatives
As NLPB progresses through this strategic action plan for 2020-2022, a distinct and clear brand for the organization will be developed to effectively communicate activities and engage with the public, registrants and stakeholders.